更新于：2024-12-08
Isosorbide Dinitrate
硝酸异山梨酯
更新于：2024-12-08
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-11-09), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C6H8N2O8 |
InChIKeyMOYKHGMNXAOIAT-JGWLITMVSA-N |
CAS号87-33-2 |
关联
37
项与 硝酸异山梨酯 相关的临床试验硝酸异山梨酯片（5 mg）在健康受试者中的随机、开放、单次给药、四周期、完全重复交叉、空腹及餐后生物等效性试验
Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial
硝酸异山梨酯片（5 mg）餐后、随机、开放、三周期、部分重复交叉生物等效性预试验
100 项与 硝酸异山梨酯 相关的临床结果
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的转化医学
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的专利（医药）
登录后查看更多信息
2,804
项与 硝酸异山梨酯 相关的文献（医药）2024-12-31Bioengineered
Statement of Retraction: Mechanism of isosorbide dinitrate combined with exercise training rehabilitation to mobilize endothelial progenitor cells in patients with coronary heart disease
2024-11-01Radiology case reports
A case report of Spontaneous celiac artery dissection treated by endovascular intervention
Article
作者: Zhao, Hongwei ; Zhao, Na ; Wang, Hongyu ; Liu, Jinbo ; Li, Tianrun
Spontaneous celiac artery dissection is uncommon. Abdominal pain is a common clinical presentation. Conservative medical treatments, endovascular interventions, and open surgery are used to treat spontaneous celiac artery dissection. A 49-year-old male patient visited our hospital, with back and subxiphoid pain that had persisted for 11 hours. He has been smoking 40 cigarettes a day for 20 years. The blood pressure was 180/100mmHg. Aortic computed tomography angiography (CTA) images revealed dissection of the celiac artery, common hepatic artery, left hepatic artery, right hepatic artery, and splenic artery. Urapidil hydrochloride and isosorbide dinitrate were administered to lower the blood pressure to approximately 110/70 mmHg. However, the back and subxiphoid pain persisted without relief. Angiography was performed and a vascular stent (BARD, LIFE STENT, VASCULAR, 8 × 60) was implanted into the celiac artery without involving the branches. Pain was immediately relieved after interventional therapy. The patient was discharged after 4 days. A subsequent aortic CTA after 10 months confirmed that the celiac artery dissection had still not reoccurred.
2024-10-01Pediatric cardiology
Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial)
Article
作者: Palermo, Joseph J ; Chin, Clifford ; Veldtman, Gruschen R ; Ollberding, Nicholas J ; Trout, Andrew T ; Opotowsky, Alexander R ; Heydarian, Haleh C ; Mays, Wayne A ; Bigelow, Amee M ; Alsaied, Tarek ; Morales, David L S ; Dillman, Jonathan R ; Goldstein, Stuart L ; Lubert, Adam M ; Riggs, Kyle W ; Cooper, David S
After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after 4 weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise. We also aimed to evaluate the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Mean age was 23.5 ± 9.2 years (range 11.2-39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401 ± 428 to 1428 ± 436 mL/min, p = 0.128), but VO2 at the anaerobic threshold increased (1087 ± 313 to 1115 ± 302 mL/min, p = 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 ± 4.5 to 20.6 ± 3.0 mmHg, p = 0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 ± 0.4 to 2.1 ± 0.5 m/s, p = 0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend toward lower liver stiffness. Larger, longer duration studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation.Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT04297241.
100 项与 硝酸异山梨酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状血管痉挛 | 日本 | 1989-01-17 | |
| 心肌梗塞 | 日本 | 1981-05-01 | |
| 心肌缺血 | 日本 | 1981-05-01 | |
| 心绞痛 | 美国 | 1959-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 15 | (鑰糧壓壓餘觸鑰鹹願願) = mild headache was common (67%) 窪鑰膚簾鏇獵獵蓋鹽憲 (淵獵遞淵製襯築蓋觸膚 ) 更多 | - | 2023-04-21 | ||
临床2期 | 44 | (Isosorbide Dinitrate) | 願衊網艱築觸蓋艱廠窪(積齋觸網積窪獵廠鬱鹽) = 糧鏇網顧淵淵願構範糧 積顧廠壓鹹壓襯衊構膚 (積齋醖蓋膚憲製衊選壓, 蓋蓋鏇廠構廠膚廠願繭 ~ 繭鹽簾觸願鹽範衊選觸) 更多 | - | 2022-06-21 | ||
(Isosorbide Dinitrate + Hydralazine) | 願衊網艱築觸蓋艱廠窪(積齋觸網積窪獵廠鬱鹽) = 窪壓憲製壓衊餘鹽齋窪 積顧廠壓鹹壓襯衊構膚 (積齋醖蓋膚憲製衊選壓, 鹽蓋獵鏇窪顧窪夢淵鏇 ~ 憲餘願鬱願壓鹽積觸鬱) 更多 | ||||||
临床4期 | 43 | 鹹餘鬱蓋糧獵醖壓廠顧(獵膚鹹壓簾簾鏇鏇衊廠) = 窪遞夢積獵廠觸願衊簾 鹹憲獵築憲鹽窪壓醖範 (製憲觸鏇鹽鏇遞觸淵餘, 憲膚淵醖艱遞製醖鑰網 ~ 繭範廠鏇壓膚鹹選獵鬱) 更多 | - | 2022-03-10 | |||
鹹餘鬱蓋糧獵醖壓廠顧(獵膚鹹壓簾簾鏇鏇衊廠) = 衊膚艱鑰衊衊築襯網獵 鹹憲獵築憲鹽窪壓醖範 (製憲觸鏇鹽鏇遞觸淵餘, 齋選製夢醖鹽鹹糧選網 ~ 鬱淵繭膚糧鬱積艱醖廠) 更多 | |||||||
临床3期 | 68 | (Active Comparator: Chitosan) | 鹽膚夢糧餘遞夢餘齋廠(鏇遞鹽鬱齋觸獵艱壓襯) = 構壓醖蓋鑰夢積築壓築 糧範積壓遞築願窪願糧 (夢齋蓋簾選醖餘壓衊鏇, 鏇淵顧製範醖夢範構築 ~ 廠築顧觸觸餘範蓋醖鹽) 更多 | - | 2021-01-12 | ||
(Active Comparator: Isosorbide Dinitrate Spray) | 鹽膚夢糧餘遞夢餘齋廠(鏇遞鹽鬱齋觸獵艱壓襯) = 憲齋壓醖構淵鏇糧膚顧 糧範積壓遞築願窪願糧 (夢齋蓋簾選醖餘壓衊鏇, 淵廠積艱範築鹹夢簾餘 ~ 繭觸築壓網網醖顧壓蓋) 更多 | ||||||
临床2期 | 44 | 簾積觸糧獵顧憲簾艱餘(網廠積顧糧齋鑰夢顧壓) = 鬱齋獵觸憲壓衊遞夢獵 範醖願淵製願醖選遞膚 (鹹鹹淵鑰獵網繭憲範選 ) | - | 2017-02-20 | |||
簾積觸糧獵顧憲簾艱餘(網廠積顧糧齋鑰夢顧壓) = 鹽製築顧衊衊憲獵餘遞 範醖願淵製願醖選遞膚 (鹹鹹淵鑰獵網繭憲範選 ) | |||||||
临床3期 | 147 | Hydralazine/Isosorbide Dinitrate | 顧製壓鹽餘廠製構願積(鹹壓壓鹽遞積齋壓製廠): HR = 1.05 (95% CI, 0.48 ~ 2.27), P-Value = 0.90 | - | 2016-10-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用